This refresh
Data-driven refresh July 16, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,235 tickers); 1,783 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.2
Health Information Services · price $22.21 · 1Y $24.56 · 5Y $35.95 · 10Y $53.33
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.7x B+ · PEG 0.59 A-
Why now. DOCS’s moat lies in its physician‑centric platform – the Doximity network and AI‑powered Ask tool embed daily workflow, creating a sticky audience that fuels premium ad and sponsorship pricing. That stickiness translates into 30.4% profit margin, 20.6% ROE and 13.1% FY revenue growth, all backed by $326 m of free cash flow. The thesis rests on the platform’s ability to keep compounding these high‑margin returns as more clinicians rely on its content and workflow tools.
Moat. The Doximity platform is the de‑facto professional social and knowledge hub for U.S. physicians, giving the company unrivaled access to a massive physician base. HIPAA‑compliant tools like Ask lock clinicians into the ecosystem, while sponsored content from pharma and health systems leverages that captive audience, creating a pricing power that underpins the 30%+ margin and 20%+ ROE.
Risk. The stock trades at a forward P/E of 22.7, well above the sector average, and the Bull Rankings model’s reverse‑DCF implies only ~4% annual FCF growth – a stark mismatch to the 13% revenue expansion, suggesting the market is already pricing in aggressive optimism. A slowdown in physician ad spend or a successful competitor’s entry could compress margins and push the price back toward its 52‑week low of $17.15, confirming the bear case.
Horizon. 1-3 yr $24.56 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $35.95 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $53.33 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.6
Software - Application · price $235.31 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 13.5x A- · PEG 0.60 A-
Why now. Adobe’s Digital Media suite, anchored by Photoshop and Premiere, is still the industry standard for creators, driving a 11.5% YoY revenue growth and delivering a 28.7% profit margin that fuels a $10.3B free cash flow engine; with a 62.8% ROE, the business compounds earnings at a pace few peers can match, and the bull case hinges on this relentless profit‑driven compounding.
Moat. The Digital Media segment’s subscription model locks in photographers, video editors, and designers with high switching costs, while the integrated Creative Cloud ecosystem creates a network effect that forces enterprises to stay within Adobe’s suite, underpinning the 62.8% ROE through pricing power and sticky recurring revenue.
Risk. The 13.5 P/E and 1.43 beta suggest the market is pricing in continued growth, but a slowdown in the 11.5% revenue growth or a rise in the 0.61 debt‑to‑equity ratio could erode margins; a sustained miss on the consensus 1‑yr target of $272.48 would confirm the over‑optimism and trigger a sell‑off.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
3. HRMY — Harmony Biosciences Holdings, Inc. · score 89.5
Biotechnology · price $33.53 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 13.5x A- · PEG 0.63 A-
Why now. Harmony’s market‑leading narcolepsy therapy WAKIX drives a 20.7% YoY revenue growth, while a 16.2% profit margin and a PEG of 0.63 prove the business is scaling profitably at a discount to peers; the combination of a rare‑disease franchise and a sub‑$35 price creates a compounding engine that will keep earnings expanding for years. The thesis hinges on WAKIX’s entrenched U.S. payer coverage and the pipeline’s ability to unlock additional rare‑neurology indications.
Moat. WAKIX’s novel mechanism and FDA approval give Harmony a protected 12‑month exclusivity in the narcolepsy market, and the company’s rare‑neurology focus creates high switching costs for neurologists who must navigate complex reimbursement for niche disorders. Pitolisant’s patented chemistry and the scarcity of comparable agents lock out generic competition for the foreseeable future, cementing pricing power.
Risk. The Bull Rankings model flags a -20%/yr free‑cash‑flow growth assumption baked into today’s price, a stark contrast to the 20.7% revenue growth and suggests the market may be over‑optimistic about sustained cash conversion; any delay in Phase 3 PWS results or weaker-than‑expected payer uptake would force the stock back toward its 52‑week low of $25.52. A confirmed miss on the pipeline would validate the bear case and crush the upside.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 89
Software - Infrastructure · price $14.59 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 22.8x B+ · PEG 0.49 A
Why now. DLocal’s dLocal for Platforms is rapidly becoming the default payment gateway for high‑growth on‑demand businesses, fueling a 46.6% YoY revenue surge, a 18% profit margin and a 34.6% ROE that together power a compounding cash‑flow machine. The combination of a $4.3b market cap, a PEG of 0.49, and a free‑cash‑flow runway of $413 m means the growth engine can keep accelerating, and the thesis rests on the platform’s ability to lock in more merchants as cross‑border commerce expands.
Moat. The pay‑in suite locks merchants into a single integration that supports hundreds of local cards, bank transfers and alternative payment methods, creating a high‑switching‑cost network that competitors can’t replicate quickly. This breadth translates into pricing power, evident in the 34.6% ROE, as DLocal can charge premium fees for the convenience and compliance it delivers across emerging markets.
Risk. The Bull Rankings model flags a reverse‑DCF implied free‑cash‑flow contraction of ‑6% per year for the next decade, meaning the current 22.8× P/E already prices in unsustainable growth; a slowdown in the platform‑payment segment or a rise in dilution would push the valuation into the red. The bear case crystallises if quarterly FCF turns negative, confirming the model’s dilution warning and collapsing the upside.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
5. INTU — Intuit Inc. · score 88.7
Software - Application · price $294.79 · 1Y $473.68 · 5Y $693.52 · 10Y $1,029
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 18.0x A- · PEG 0.73 A-
Why now. Intuit’s QuickBooks Online platform, bolstered by Mailchimp’s marketing automation, is powering a 15.1% YoY revenue growth while the business converts that top‑line expansion into a 21.9% profit margin and a stellar 22.2% ROE, creating a high‑quality cash engine that can compound for years to come. The thesis rests on the relentless stickiness of SMB subscription revenue and the ability to cross‑sell financial and marketing services, ensuring the growth engine stays hot.
Moat. The QuickBooks ecosystem locks small‑and‑mid‑market businesses into an integrated suite of accounting, payroll, payments and financing tools, creating switching costs that rival any SaaS rival. Coupled with Mailchimp’s CRM and automation, Intuit captures a larger share of each customer’s spend, and its pricing power in the SMB segment fuels the high ROE.
Risk. The Bull Rankings model flags a reverse‑DCF implied free‑cash‑flow growth of -5%/yr over the next decade, meaning the current price already assumes cash generation outpacing the modest growth rate. If revenue growth decelerates or margins compress, the stock’s valuation—already priced for aggressive growth—could tumble, confirming the bear case.
Horizon. 1-3 yr $473.68 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $693.52 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,029 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.4
Drug Manufacturers - Specialty & Generic · price $171.55 · 1Y $199.27 · 5Y $291.76 · 10Y $432.80
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.4x B · PEG 0.49 A
Why now. NBIX is poised to compound earnings on its entrenched neuro‑psychiatric franchise, anchored by INGREZZA’s expanding indication set and Orilissa’s dominant position in endometriosis, driving 28.6% YoY revenue growth, 21.6% profit margin, and a sub‑1.0 PEG of 0.49 that signals the market is undervaluing its growth trajectory.
Moat. The company’s moat lives in its FDA‑approved, patent‑protected therapies for rare movement and endocrine disorders, giving it pricing power that fuels a near‑20% ROE (19.6%) and a defensible market share in niche indications that competitors cannot quickly replicate.
Risk. The stock trades at a lofty P/E of 26.4 while the Bull Rankings model’s reverse‑DCF assumes an unsustainable 11% annual free‑cash‑flow growth far above the current 28.6% revenue pace, leaving little room for a slowdown before the valuation collapses; a miss on any upcoming label expansion would trigger a rapid re‑rating.
Horizon. 1-3 yr $199.27 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $291.76 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $432.80 if current growth sustains into durable earnings power.
7. LRN — Stride, Inc. · score 86.8
Education & Training Services · price $87.62 · 1Y $100.76 · 5Y $147.53 · 10Y $218.85
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 13.7x A- · PEG 0.49 A
Why now. Stride’s integrated virtual‑school platform is rapidly becoming the default solution for districts shifting to blended learning, driving a 10.9% YoY revenue growth while delivering a solid 12.2% profit margin and generating $414 m of free cash flow. The combination of a low‑cost, cloud‑based curriculum stack and a recurring‑revenue model fuels a compounding earnings engine that can sustain double‑digit growth for years. The thesis hinges on the platform’s ability to lock in long‑term contracts that keep cash flowing and margins expanding.
Moat. LRN’s moat lies in its end‑to‑end virtual‑school suite, which bundles curriculum, enrollment, progress tracking and support services into a single, highly integrated system. School districts face costly migration and data‑integration hurdles, creating a high switching cost that protects recurring revenue. This lock‑in, coupled with the company’s 18.8% ROE, stems from pricing power in a niche where few competitors can match the breadth of the integrated offering.
Risk. The market is pricing in a reverse‑DCF implied free‑cash‑flow contraction of –9% annually for the next decade, far below the current 10.9% revenue growth rate; any slowdown in enrollment or margin pressure would validate this pessimistic view and trigger a sharp sell‑off. A modest dip in the virtual‑school adoption curve or a successful competitor launch could compress the 12.2% margin, confirming the bear case. The key trigger would be a quarterly earnings miss that forces the implied FCF growth into negative territory.
Horizon. 1-3 yr $100.76 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $147.53 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $218.85 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 85.5
Semiconductors · price $207.40 · 1Y $301.97 · 5Y $442.11 · 10Y $655.84
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 31.8x B · PEG 0.65 A-
Why now. NVIDIA’s AI‑driven data‑center compute platform is the engine of its next growth wave, with the Compute & Networking segment delivering 70.7% YoY revenue growth, 63% profit margin and a staggering 81.7% ROE that fuels cash generation of $119.1 B of free cash flow. This compounding profit engine, anchored in the exploding demand for accelerated AI workloads, will keep the business expanding at a secular rate far above the market’s 10‑yr average. The thesis rests on the relentless adoption of NVIDIA’s data‑center GPUs across cloud, enterprise and automotive AI workloads.
Moat. The moat lives in NVIDIA’s proprietary GPU architecture and CUDA software ecosystem that lock in the world’s largest hyperscale and enterprise customers to its Compute & Networking platform. Switching costs are massive because developers write AI models in CUDA, creating a network effect that rivals cannot replicate quickly, while the company’s pricing power in the high‑margin AI accelerator market drives the 81.7% ROE.
Risk. The bull case hinges on continued AI spend, but a slowdown in data‑center capex or a breakthrough from a rival accelerator could compress the lofty PE of 31.8x and erode the 63% margin, especially given NVIDIA’s high beta of 2.21 that amplifies downside volatility. A sustained dip below the 52‑week low of $164.07 would signal that growth expectations are overstated and could trigger a sharp sell‑off.
Horizon. 1-3 yr $301.97 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $442.11 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $655.84 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.4
Information Technology Services · price $28.69 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 18.3x A- · PEG 0.88 B+
Why now. EXLS is the premier AI‑powered claims‑management engine for insurers, and that moat is fueling a 13.4% YoY revenue growth while delivering a 32.3% ROE and a $297 m free‑cash‑flow run‑rate. The combination of high‑margin digital operations and a sticky insurance client base means earnings will keep compounding, making the current price a launchpad for outsized upside.
Moat. Its AI‑driven analytics platform embeds directly into insurers’ claims, underwriting and policy servicing workflows, creating high switching costs and enabling pricing power that drives the 32.3% ROE. The same data engine is cross‑sold to healthcare, banking and other regulated sectors, locking in multi‑industry contracts that competitors can’t replicate quickly.
Risk. The Bull Rankings model flags a reverse‑DCF implied 0% free‑cash‑flow growth, meaning the market already prices in a flat‑line outlook despite the 13.4% revenue expansion; any slowdown in AI spend by insurers or a margin dip would force the stock down. A debt‑to‑equity of 0.67 adds leverage risk if cash conversion falters, and a P/E of 18.3 is high for a company whose growth may decelerate, making the next earnings beat the key litmus test for the bull case.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
10. ADMA — ADMA Biologics, Inc. · score 84.1
Biotechnology · price $8.81 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 13.0x A- · PEG 0.66 A-
Why now. ADMA’s IVIG franchise—anchored by BIVIGAM and ASCENIV—continues to compound earnings as revenue climbs 11% YoY, profit margins sit at a robust 32.4%, and ROE soars to 42.4%. The combination of high‑margin plasma‑derived biologics and a captive collection network fuels sustainable growth, and the entire thesis hinges on the ability to keep expanding the IVIG market share.
Moat. The plasma‑collection centers give ADMA exclusive access to a scarce raw material, creating a supply moat that forces hospitals to stay with ADMA’s IVIG products rather than switch to competitors. This captive supply, coupled with pricing power from being a category leader in primary humoral immunodeficiency treatment, underpins the high ROE and protects margins.
Risk. The market is already pricing in aggressive growth—our reverse‑DCF implies only 3%/yr free‑cash‑flow expansion versus the actual 11% revenue growth—so any slowdown or margin compression would force a re‑rating. Additionally, a debt‑to‑equity of 1.11 adds financial leverage risk if cash flow falters. A miss on growth expectations would trigger a sell‑off and break the compounding narrative.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.6
Auto & Truck Dealerships · price $36.02 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 19.0x B · PEG 1.03 B+
Why now. CarGurus’ Digital Deal platform is turning its massive dealer network into a high‑margin, online‑first sales funnel, and that engine is now running at 15.9% profit margin on $3.2b market cap while revenue still climbs 14% YoY. With a PE of 19 and a PEG of 1.03, the market is already pricing in growth, but the real kicker is the 62.9% ROE generated by the subscription‑driven dealer fees and advertising moat – a compounding engine that should stay north of historical returns as more shoppers shift online. The thesis rests on Digital Deal expanding its share of the online automotive marketplace, feeding the same high‑margin earnings that underpin the current valuation.
Moat. The moat lives in CarGurus’ integrated dealer subscription and advertising suite, which locks dealers into a data‑rich marketplace where switching costs are high because listings, pricing analytics, and lead generation are all bundled. This network effect fuels a pricing premium reflected in the 62.9% ROE, a level only achievable when dealers can’t easily replicate the platform’s scale and buyer‑seller matching algorithms.
Risk. The bull case hinges on continued dealer stickiness, but a surge of competing marketplaces or a shift back to in‑person buying could erode that advantage; the stock trades at a PE of 19, well above the sector average, and the Bull Rankings model flags a reverse‑DCF implied free‑cash‑flow growth of –1%/yr, meaning any slowdown in the 14% revenue growth or margin compression would make the valuation look overly optimistic. A breach of the 52‑week low at $26.39 would confirm the bear narrative and force a re‑rating.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.2
Information Technology Services · price $87.67 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.6x A · PEG 0.44 A
Why now. EPAM’s digital platform engineering franchise is exploding in the cloud‑migration wave, driving 14.2% revenue growth YoY while delivering $544 m of free cash flow and a rock‑bottom PE of 12.6×. The combination of high‑margin software services and a disciplined balance sheet fuels a compounding earnings engine that will keep accelerating as enterprises double‑down on AI‑enabled platforms. The thesis rests on the persistence of this growth‑driven cash generation.
Moat. EPAM’s moat lives in its end‑to‑end engineering platform that couples custom software development with cloud, data, AI, and cybersecurity services, creating deep integration and high switching costs for large enterprise clients. Its ability to deliver a single‑source solution across the entire digital transformation stack locks in multi‑year contracts and protects margins, while the low debt‑to‑equity of 0.08 lets it reinvest cash without financing constraints.
Risk. The stock’s upside is vulnerable to a slowdown in enterprise cloud spend and the high beta of 1.43, which amplifies market volatility; a deceleration of revenue growth below the current 14.2% would pressure the modest PE multiple and expose the weakest pillar—Quality (score 72). A sustained miss on growth expectations would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
13. RMD — ResMed Inc. · score 83.1
Medical Instruments & Supplies · price $202.76 · 1Y $252.20 · 5Y $369.25 · 10Y $547.75
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 19.6x B+ · PEG 1.13 B+
Why now. ResMed’s dominance in cloud‑connected sleep diagnostics – anchored by the NightOwl and ApneaLink Air platforms – is turning the fragmented sleep‑apnea market into a sticky, recurring‑revenue engine. The business is delivering 10.3% YoY revenue growth, a 27.4% profit margin and a 23.4% ROE, all while expanding its software‑as‑a‑service footprint. The thesis rests on the compounding power of this hardware‑software moat, which should keep earnings expanding at double‑digit rates for years to come.
Moat. ResMed’s integrated hardware‑software suite creates a high switching cost for sleep clinics and home‑care providers; clinicians must retrain and re‑validate data pipelines to move away from the proprietary cloud platform. This lock‑in, combined with FDA‑cleared devices and a data‑rich SaaS layer, fuels pricing power that underpins the 23.4% ROE – a return that rivals only the most entrenched medical‑device leaders.
Risk. The market is pricing in a near‑term earnings multiple that may be stretched: a forward P/E of 19.6 implies growth far above the reverse‑DCF implied free‑cash‑flow growth of just ~1% per year. If revenue decelerates from the current 10.3% pace or margins compress, the valuation gap collapses. A sustained slowdown in new‑device adoption or a disruptive home‑diagnostic entrant would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $252.20 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $369.25 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $547.75 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 82.7
Information Technology Services · price $142.89 · 1Y $164.23 · 5Y $240.45 · 10Y $356.69
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 14.1x A- · PEG 0.54 A-
Why now. Gartner’s Insights subscription platform, the cash‑generating engine of its three‑segment model, is expanding at a steady 2.3% revenue growth while delivering a healthy 11.4% profit margin and a robust $1.3 B free cash flow run‑rate. Coupled with a modest P/E of 14.1 and a sub‑1.0 PEG of 0.54, the stock is priced for continued compounding of its high‑margin cash flow, making the upside hinge on the durability of its subscription moat.
Moat. The Insights segment locks in enterprise clients through multi‑year subscriptions to proprietary research, benchmark data, and direct access to Gartner’s expert network, creating high switching costs and a sticky revenue base. Gartner’s global conference franchise further entrenches relationships, reinforcing the subscription moat and limiting competitive encroachment.
Risk. Growth is the weakest pillar in our model (Growth score 65) and revenue is only ticking up at 2.3% YoY, far below the sector’s growth expectations; the reverse DCF suggests the market is betting on a -13% annual free‑cash‑flow growth for the next decade, so any slowdown or margin compression would quickly erode valuation. A breach of the 52‑week low ($124.25) would confirm that the optimism is overstated and the bull thesis collapses.
Horizon. 1-3 yr $164.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $240.45 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $356.69 if current growth sustains into durable earnings power.
15. VEEV — Veeva Systems Inc. · score 82.1
Health Information Services · price $197.37 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 35.0x C+ · PEG 0.87 B+
Why now. The bull case hinges on Veeva’s dominant Veeva Vault CRM Suite, which locks pharmaceutical and biotech customers into a single, cloud‑native workflow, driving relentless subscription expansion. The business is growing revenue at 16.2% YoY, converting that into a 28.4% profit margin and generating $1.7B of free cash flow on a $32.1B market cap – a cash‑rich engine that compounds as more brands adopt the platform. The thesis rests on the continuation of this high‑margin, high‑growth subscription model outpacing the 8% FCF growth baked into today’s price.
Moat. Veeva’s moat is the deep integration of its Commercial Cloud – especially Vault CRM and PromoMats – into regulated drug‑launch processes, creating switching costs that are hard for generic SaaS rivals to replicate without costly compliance rebuilds. This lock‑in fuels a ROE of 12.9%, reflecting pricing power from being the de‑facto data and workflow backbone for life‑science firms worldwide.
Risk. The bear case centers on valuation stretch: a forward P/E of 35 far exceeds the sector average and assumes growth far above the historical 16.2% revenue pace, while the reverse‑DCF shows the market demanding an 8% annual FCF growth rate that outstrips the company’s actual trajectory. A slowdown to sub‑10% revenue growth or margin compression would expose the premium, and a breach of the 52‑week low at $148.05 would trigger a sell‑off.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
16. CVSA — Covista Inc. · score 80.8
Education & Training Services · price $116.22 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +9.7% B · D/E 0.54 B+ · P/E 16.9x B+ · PEG 0.88 B+
Why now. Covista’s Chamberlain and Walden online degree platforms are rapidly scaling in the booming U.S. healthcare education market, driving a sustainable earnings engine. Revenue is growing 9.7% YoY while free cash flow sits at a healthy $336 m, delivering a free‑cash‑flow yield of roughly 8.4% on a $4.0 b market cap. Coupled with a modest PE of 16.9x and a PEG of 0.88, the stock is primed to compound as enrollment expands, making the upside hinge on continued segment‑level growth.
Moat. The Chamberlain and Walden segments benefit from deep integration with professional licensing pathways, creating high switching costs for students who have invested in accredited curricula and credit transfer agreements. This lock‑in, together with a ROE of 17.2% driven by pricing power in niche health‑profession programs, limits competitive encroachment and sustains margin expansion.
Risk. The primary risk is the modest debt load (D/E 0.54) combined with a valuation premium that already reflects aggressive growth assumptions; a slowdown in enrollment or tighter regulatory scrutiny could compress the PE of 16.9x and erode margins. A breach of the 52‑week low ($86.97) would signal that the market is pricing in a deceleration, confirming the bear case.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
17. DXCM — DexCom, Inc. · score 80.6
Medical Devices · price $77.98 · 1Y $85.46 · 5Y $125.12 · 10Y $185.61
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 33.5x C+ · PEG 1.38 B
Why now. Dexcom’s G7 platform is about to dominate the CGM market, and its integrated Share remote‑monitoring ecosystem locks in endocrinologists and patients, fueling a compounding growth engine. The company is delivering 16.1% YoY revenue growth, 19.3% profit margin and a stellar 31.5% ROE, all on a free‑cash‑flow runway of $1.4 B. The thesis rests on the G7’s rapid adoption translating into sustained high‑single‑digit compounding for years to come.
Moat. Dexcom’s moat comes from its end‑to‑end CGM ecosystem – the G7 sensor, the Share cloud service and the Follow app – which creates switching costs for both physicians and patients who rely on real‑time data integration. This clinical stickiness, combined with pricing power that underpins a 31.5% ROE, cannot be duplicated quickly by rivals lacking FDA‑cleared integrated hardware and software.
Risk. The stock trades at a lofty PE of 33.5 and a beta of 1.45, implying market expectations far above the historic 16% revenue growth; our reverse‑DCF shows the price assumes ~20% free‑cash‑flow growth for a decade, a level not yet proven. A slowdown in G7 adoption or a pricing squeeze would force the valuation down, and a rise in debt‑to‑equity above 0.5 would amplify the downside. The bear case is confirmed if the 12‑month price falls below the 52‑week low of $54.11.
Horizon. 1-3 yr $85.46 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $125.12 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $185.61 if current growth sustains into durable earnings power.
18. APP — AppLovin Corporation · score 80.2
Advertising Agencies · price $434.48 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 37.8x C+ · PEG 1.23 B
Why now. AppLovin’s growth engine is its MAX in‑app bidding platform, which is driving a staggering 66.4% YoY revenue growth while delivering a 64.3% profit margin and generating $4.4 B of free cash flow. The combination of ultra‑high margin earnings and a market‑leading AI ad stack means cash can compound at the 41% / yr rate the reverse‑DCF assumes, leaving upside for any slowdown in that assumption. The entire thesis rests on the persistence of MAX’s network‑effect‑driven inventory capture.
Moat. MAX creates a real‑time competitive auction that locks publishers into AppLovin’s ecosystem, because each additional advertiser improves the auction’s price discovery and reduces the cost of switching. Coupled with Adjust’s analytics suite, advertisers gain a one‑stop shop that rivals can’t replicate without rebuilding both the bidding engine and the measurement stack, cementing a durable switching‑cost barrier.
Risk. The stock trades at a lofty PE of 37.8 and a beta of 2.48, implying that any deceleration in the current 66.4% revenue growth or a margin squeeze would force a sharp re‑rating. A debt‑to‑equity of 1.63 adds financial leverage risk if cash generation falters. A sustained drop in growth or a widening of the spread between revenue and free‑cash‑flow growth would trigger a sell‑off and invalidate the bull case.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
19. MELI — MercadoLibre, Inc. · score 79.3
Internet Retail · price $1857.42 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 48.9x D · PEG 1.16 B+
Why now. MercadoLibre’s moat is its integrated commerce‑to‑payments ecosystem, anchored by Mercado Pago, which fuels a 36.4% YoY revenue growth and a 26.4% ROE that outpaces peers, while the market still rewards that growth at a lofty PE of 48.9x. The compounding engine is the seamless loop of Marketplace sales, payment processing, credit, and logistics that keeps users locked in and expands the addressable market across Brazil, Mexico, and Argentina. The thesis rests on the persistence of this virtuous cycle delivering double‑digit top‑line growth.
Moat. The moat lives in the network effect of Mercado Pago, which processes billions of transactions for both buyers and sellers on the Marketplace, creating data‑driven credit underwriting (Mercado Credito) and high‑margin financial services that rivals cannot replicate quickly. This integrated stack drives pricing power, evident in a 26.4% ROE, and locks merchants into a one‑stop shop for sales, payments, and logistics.
Risk. The stock trades at an elevated PE of 48.9x and a debt‑to‑equity of 1.7, implying leverage risk and a valuation that assumes continued 36% revenue expansion—any slowdown or margin compression would expose the premium. A sustained dip in growth or a rise in financing costs would validate the bearish view that the price already embeds excessive optimism.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
20. PODD — Insulet Corporation · score 79.3
Medical Devices · price $164.43 · 1Y $238.22 · 5Y $348.77 · 10Y $517.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 38.4x C+ · PEG 1.40 B
Why now. The Omnipod 5 automated insulin delivery system is unlocking next‑generation diabetes care, and its rapid adoption is fueling a revenue surge of 31.9% YoY while delivering a healthy 10.4% profit margin and a ROE of 23.2%—a rare growth‑value blend in MedTech. Management’s focus on expanding the Bluetooth‑enabled pod ecosystem promises compounding revenue growth that will persist as more patients switch from pump‑to‑patch therapy. The entire thesis hinges on the Omnipod platform’s ability to capture a larger share of the insulin‑delivery market and keep the growth engine humming.
Moat. Insulet’s moat lives in the Omnipod platform’s proprietary AID algorithm and seamless Bluetooth integration, which lock patients into a closed‑loop system that is hard to replicate without extensive FDA clearance and software validation. The pod’s disposable design creates high switching costs for users accustomed to the pod‑and‑manager workflow, while the company’s pricing power—evidenced by a 23.2% ROE—stems from category leadership in patch‑based insulin delivery.
Risk. At a forward P/E of 38.4, the stock is priced for a sustained 21% annual free‑cash‑flow expansion—well above the 31.9% revenue growth that currently powers the valuation, leaving little margin for error. Any slowdown in Omnipod adoption, a competitive breakthrough from rival patch systems, or a rise in debt‑to‑equity above 0.78 could compress margins and trigger a sell‑off. A breach of the 52‑week high ceiling (currently $354.88) without corresponding growth would confirm the over‑optimism and topple the bull case.
Horizon. 1-3 yr $238.22 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $348.77 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $517.38 if current growth sustains into durable earnings power.
21. FIVE — Five Below, Inc. · score 78.4
Specialty Retail · price $197.71 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 24.9x C+ · PEG 0.98 B+
Why now. Five Below’s relentless expansion of its personalized living‑space assortment – from lamps and novelty décor to plush pillows – is fueling a revenue surge of 25.9% YoY, while its free‑cash‑flow generation of $505 m and a sub‑1.0 PEG of 0.98 prove the growth is cash‑rich and sustainable; the whole thesis hinges on this compounding top‑line momentum persisting as the teen‑and‑young‑adult value shopper base deepens.
Moat. The company’s moat lives in its ultra‑low‑price, high‑turnover product mix that locks in price‑sensitive Gen‑Z shoppers who visit weekly for novelty décor, party goods and trend‑driven accessories – a segment where competitors struggle to match Five Below’s SKU breadth and floor‑space efficiency, enabling a 19% ROE driven by pricing power in a niche where consumers expect value and variety.
Risk. The bull case is priced in: a forward P/E of 24.9 is lofty for a specialty retailer, and any slowdown from the current 25.9% revenue growth would compress margins that are already modest at 8.7%; a debt‑to‑equity of 0.86 adds leverage risk, and a beta of 1 means market swings will hit the stock hard. A miss on quarterly revenue growth or a margin dip below 8% would validate the bear view and topple the upside.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 78.1
Footwear & Accessories · price $109.03 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.5x B+ · PEG 1.33 B
Why now. The HOKA performance‑footwear franchise is accelerating, driving a 9.8% YoY revenue growth while the business converts that into a 18.7% profit margin and a stellar 41% ROE, delivering compounding earnings that can sustain the upside. With a low‑debt balance sheet (D/E 0.15) and a buy‑back program, the stock is positioned to capture the next wave of premium active‑lifestyle demand. The thesis rests on HOKA’s continued market‑share gains translating into persistent earnings compounding.
Moat. Deckers leverages the category leadership of HOKA and UGG to command pricing power in premium footwear, reflected in its 41% ROE, while its direct‑to‑consumer and selective retail distribution limits channel dilution. The niche expertise in high‑performance running and trail shoes creates switching costs for serious athletes, and the low‑leverage balance sheet lets Deckers reinvest cash without diluting shareholders.
Risk. The market is pricing in a forward P/E of 15.5, which is modest for a growth name, but the Bull Rankings model’s reverse DCF shows the current price assumes a mere 4% annual free‑cash‑flow growth for the next decade—well below the 9.8% revenue growth rate, indicating optimism may be overstated. A slowdown in HOKA’s premium pricing or a broader consumer‑spending dip would compress margins and could push the stock toward its 52‑week low of $78.91, confirming the bear case.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 77.9
Entertainment · price $74.35 · 1Y $111.03 · 5Y $162.56 · 10Y $241.15
FCF $11.9b A- · Rev +16.7% B+ · D/E 0.54 B · P/E 24.0x B · PEG 1.44 B
Why now. Netflix’s global streaming platform is the only subscription service that combines a massive library of TV series, documentaries, feature films, games and live programming on every internet‑connected device, driving relentless subscriber stickiness. That stickiness fuels a 28.5% profit margin, a 43% ROE and a 16.7% YoY revenue growth—a rare trio that guarantees cash‑flow compounding as the market expands. The whole thesis hinges on the ability to keep scaling this high‑margin content engine year after year.
Moat. The moat lives in Netflix’s content‑distribution ecosystem: members stream on TVs, set‑top boxes and mobiles worldwide, creating a switching cost that rivals can’t match without rebuilding a comparable library and device integration. Its 28.5% margin and 43% ROE stem from pricing power earned by being the category leader in on‑demand streaming, allowing it to fund original productions that lock users into the platform.
Risk. The bear case is the elevated valuation – a forward P/E of 24 versus a 16‑year‑high 52‑week price of $127.75 – which assumes growth far outpacing the 16.7% revenue rise. Any slowdown in subscriber acquisition or a rise in debt‑to‑equity above 0.54 would crush the margin cushion, and a beta of 1.52 makes the stock vulnerable to market swings. A breach of the 52‑week low ($70.86) would confirm that the optimism is over‑priced and trigger a sell‑off.
Horizon. 1-3 yr $111.03 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $162.56 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $241.15 if current growth sustains into durable earnings power.
24. META — Meta Platforms, Inc. · score 77.7
Internet Content & Information · price $664.54 · 1Y $826.63 · 5Y $1,210 · 10Y $1,795
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 24.1x B · PEG 0.96 B+
Why now. Meta’s Family of Apps continues to compound revenue at a blistering 26.2% YoY while extracting a razor‑thin 32.8% profit margin, driving an industry‑leading 29% ROE that fuels free‑cash‑flow growth—this high‑margin ad engine and its expanding VR ecosystem will keep cash compounding for years, and the thesis rests on that relentless cash generation.
Moat. The FoA segment’s network effects lock users into Facebook, Instagram and Messenger, creating a data moat that translates into pricing power for advertisers, while Reality Labs leverages the same user base to seed adoption of VR/AR hardware that competitors cannot replicate quickly due to massive platform integration costs.
Risk. At a forward P/E of 24.1 and a beta of 1.25, the stock is priced for continued high‑growth; any slowdown in the 26.2% revenue acceleration or a margin squeeze would force the valuation down, and a rise in debt‑to‑equity above 0.36 would amplify the downside. A miss on growth expectations would be the trigger that invalidates the bull case.
Horizon. 1-3 yr $826.63 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,210 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,795 if current growth sustains into durable earnings power.
25. MU — Micron Technology, Inc. · score 77.4
Semiconductors · price $853.20 · 1Y $1,490 · 5Y $2,181 · 10Y $3,235
FCF $26.2b A · Rev +167.0% A · D/E 0.06 A- · P/E 19.3x B+ · PEG 0.13 A
Why now. Micron’s dominance in the Cloud Memory Business Unit is set to turbo‑charge earnings as AI‑driven data centers snap up high‑bandwidth and CXL‑based memory, delivering a staggering 167% YoY revenue growth, a razor‑thin 55.9% profit margin and a peer‑shattering 50.1% ROE. Those fundamentals make the current price a leveraged bet on continued compounding in the AI‑fuelled memory market.
Moat. The company’s high‑bandwidth and CXL memory modules lock in data‑center customers with costly redesigns and strict latency specs, giving Micron pricing power that translates into a 50% ROE. Its multi‑segment footprint—from mobile LPDDR to automotive embedded storage—spreads risk while the proprietary process technology creates a cost advantage competitors can’t quickly replicate.
Risk. A 2.14 beta and a reverse‑DCF implied 44% annual free‑cash‑flow growth far outpace realistic revenue expansion, meaning the stock is priced for perfection; a slowdown in AI‑driven demand or a pricing squeeze would force the P/E of 19.3 to compress. The bear case crystallises if quarterly revenue growth falls below 100% and the margin slides, triggering a sharp correction toward the 52‑week low.
Horizon. 1-3 yr $1,490 (analyst consensus (n=42)) — fundamentals + valuation re-rating. 5 yr $2,181 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $3,235 if current growth sustains into durable earnings power.
26. YUMC — Yum China Holdings, Inc. · score 76.4
Restaurants · price $44.33 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 17.0x B+ · PEG 1.08 B+
Why now. Yum China's KFC and Pizza Hut brands are accelerating online food‑delivery penetration, fueling a 6.7% revenue growth while preserving a 7.8% profit margin and delivering $931 m of free cash flow. This operating engine translates into a solid 17.4% ROE and underpins a compounding earnings trajectory that will keep cash generation expanding for years to come.
Moat. The franchise model gives Yum China exclusive rights to operate KFC, Pizza Hut, Taco Bell and other concepts across China, locking in a dense network of high‑traffic locations and a proprietary supply chain that delivers consistent product quality at scale. This distribution advantage creates pricing power and cost efficiencies that drive the 17.4% ROE, a level hard for new entrants to replicate quickly.
Risk. Growth is already modest at only 6.7% YoY, and the Bull Rankings model assumes a 6% annual free‑cash‑flow growth that may be unrealistic if online delivery stalls or competition intensifies. A slowdown in revenue growth or margin compression would force the stock toward its 52‑week low of $40.15, confirming the bear case.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. FISV — Fiserv, Inc. · score 75.7
Sector n/a · price $51.72 · 1Y $67.37 · 5Y $85.05 · 10Y $109.08
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.8x A- · PEG 2.43 C
Why now. Sector n/a · market cap $27.6b. Down 69% from 52-week high of $168.02 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $67.37 (implying +30% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 69% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $67.37 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $85.05 at ~10% CAGR — dividend + buyback compounding. 10 yr $109.08 if the moat survives secular pressure.
28. ULTA — Ulta Beauty, Inc. · score 75.1
Specialty Retail · price $478.86 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 18.0x B · PEG 1.63 C+
Why now. Specialty Retail · market cap $20.6b. Down 33% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +30% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 33% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
29. EME — EMCOR Group, Inc. · score 74.9
Engineering & Construction · price $750.04 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A · P/E 25.2x B+ · PEG 0.41 A
Why now. Engineering & Construction · market cap $33.4b. Down 21% from 52-week high of $951.96 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +33% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
30. DEO — Diageo plc · score 74.3
Beverages - Wineries & Distilleries · price $85.48 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 19.8x B · PEG 0.79 A-
Why now. Beverages - Wineries & Distilleries · market cap $47.5b. Down 27% from 52-week high of $116.41 — deep drawdown territory. PEG 0.79 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $101.14 (implying +18% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Dividend payout 96% of earnings on a 4.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.